Auron Therapeutics is developing next-generation targeted cancer therapies by identifying and targeting the drivers of the disrupted cell states found in cancer, and reverting cancer cells from a plastic, proliferative cell state to a more mature, non-proliferative cell state. Using its AURIGIN™ platform, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, for the treatment of both solid tumors and hematologic malignancies.
Auron Therapeutics Announces FDA Clearance to Initiate Clinical Development of AUTX-703 and Completion of Series B Financing
Newton, MA, February 4, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced progress for its lead KAT2A/B program and clinical candidate, AUTX-703, and the completion of a $27 million Series B financing.